Communiqués AstraZeneca PLC

Actions

AZN

GB0009895292

Produits pharmaceutiques

Marché Fermé - London S.E. Autres places de cotation 17:35:10 10/04/2026			Varia. 5j.	Varia. 1 janv.
15 230,00 ^GBX	-0,30 %		-0,56 %	+10,44 %

10/04	ASTRAZENECA : Opinion positive de UBS	ZD
10/04	Berenberg passe à l'achat sur Elixirr International	AN

Communiqués

09/04	AstraZeneca : Special Business Approved at AGM	PU
09/04	AstraZeneca : Results of Annual General Meeting held on 9 April 2026 (Results of Annual General Meeting held on 9 April 2026)	PU
08/04	AstraZeneca : Sustainability Data Reporting Criteria 2025	PU
08/04	AstraZeneca : Assurance Report for Sustainability Data Annex 2025	PU
08/04	AstraZeneca : Sustainability Data Annex 2025	PU
02/04	IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer	BU
02/04	AstraZeneca : Imfinzi plus Imjudo combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in embolisation-eligible unresectable liver cancer in EMERALD-3 Phase III trial	PU
31/03	University of Glasgow: Simple screening blood test could help identify undiagnosed heart failure in people living with diabetes	AQ
27/03	Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD	BU
27/03	AstraZeneca : Tozorakimab met OBERON/TITANIA primary endpoints	PU
23/03	OMP Positioned Highest for Both Completeness of Vision and Ability to Execute in the 2026 Gartner(R) Magic Quadrant(TM) for Supply Chain Planning Solutions: Process Industries	AQ
20/03	UK-First AI Case-Finding Pathway Launched to Improve Early Detection of Oesophageal and Gastric Cancer	AQ
11/03	FDA Grants Priority Review to ENHERTU in Post-Neoadjuvant HER2-Positive Early Breast Cancer: A Market-Shaping Milestone \| AstraZeneca and Daiichi Sankyo	AQ
10/03	AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer	BU
10/03	AstraZeneca : PSP share plan rules - for shareholder approval at 2026 AGM	PU
10/03	AstraZeneca : Notice of AGM (Notice of Meeting 2026)	PU
09/03	Koselugo approved in Canada for plexiform neurofibromas in adults with neurofibromatosis type 1	AQ
09/03	ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer	BU
09/03	AstraZeneca : Enhertu granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer	PU
04/03	Preclinical takeaways from the World ADC Conference London	AQ
24/02	AstraZeneca : Directorate change	PU
20/02	CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting	BU
13/02	Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine	BU
11/02	AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US	BU
11/02	Astrazeneca re-doses $80bn annual sales goal	AQ